IndustryCompany release

Jazz lifts 2026 revenue guidance after Ziihera approval and Actio acquisition

🇺🇸 Jazz Pharmaceuticals plc (JAZZ) · Mon 02 Nov 2026

Jazz Pharmaceuticals reported Q3 2026 revenue of $1.24bn, up 10%, and raised its full-year outlook, while booking a GAAP net loss driven by a $754m IPR&D charge.

Jazz Pharmaceuticals reported third-quarter 2026 revenue of $1.24 billion, an increase of 10% on the same period last year. The company raised its 2026 revenue guidance to a range of $4.775 billion to $4.85 billion.

A key regulatory event in the period was the US Food and Drug Administration's approval of Ziihera on 25 August 2026 for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. Jazz also closed its acquisition of Actio, which adds the KCNT1 epilepsy candidate ABS-1230 to its pipeline.

Despite the higher revenue, Jazz recorded a GAAP net loss for the quarter, which it attributed to an in-process research and development (IPR&D) charge of $754 million. The company also placed $1.25 billion of exchangeable notes and announced a new $500 million share buyback.

Looking ahead, the FDA has set a PDUFA goal date of 16 April 2027 for Jazz's oral cannabidiol capsules. A PDUFA date is the target by which the agency aims to complete its review of a marketing application.

What it means for your team

  • Ziihera's first-line HER2-positive gastroesophageal adenocarcinoma approval marks a new US commercial and market-access workstream for Jazz's oncology portfolio.
  • The Actio deal brings ABS-1230, a KCNT1 epilepsy candidate, into Jazz's pipeline, so regulatory teams should expect development planning around it.
  • The 16 April 2027 PDUFA date for oral cannabidiol capsules is the next FDA decision point disclosed by the company.

Company's press release (SEC filing): Jazz Pharmaceuticals plc ↗

Article written by VigiEye from the official source (Jazz Pharmaceuticals plc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →